It is well known that profoundly deaf patients can have their hearing improved by cochlear implant (CI). However, for those patients with cochlear nerve damage or even complete loss of nerve function, hearing cannot be improved by cochlear implant due to the lack of complete cochlear nerve function. Auditory brainstem implant (ABI) is designed for these patients who lack complete cochlear nerve function. Auditory brainstem implantation (ABI) is designed for these patients who lack complete cochlear nerve function. auditory brainstem implantation, i.e., the electrode is implanted into the cochlear nucleus of the brainstem, and the sound signal is converted into electric signal to stimulate the cochlear nerve through the extracorporeal receiver to form the auditory pathway. aBI is suitable for the patients who suffer from neurofibromatosis type 2 (NF2), poor tympanic ventricular pneumatization, neurological deafness, and the effect of cochlear implantation is not good. Currently, there are about 100,000 such patients in China, and the number is increasing by about 6,000 per year, so there is an urgent need for this new treatment technology. ABI is also divided into two parts: the implantation part consists of electrodes, cables and receivers, and the stimulator, while the external part includes a transmitter coil, a pickup (electroacoustic transducer), a speech processor, and connecting wires. First, after the electrodes are implanted into the cochlear nucleus of the patient’s brainstem by ABI implantation surgery, activation of the ABI device begins 4-8 weeks after the implantation surgery. Hearing improvement in patients receiving ABI is a relatively slow process, requiring a period of speech training to gradually stimulate the cochlear nerve and restore their hearing. Improvements in sound perception, including recognition of open speech, may take several years in some patients, and there are even patients whose auditory behavior continues to improve 8 years after ABI implantation. Therefore, we followed up patients every 3 months during the first year of electrode implantation and annually thereafter, periodically evaluating the patient’s response to the individual stimulating electrodes and modulating the program within the sound processor appropriately. The ABI can safely and effectively provide usable hearing to most NF2 patients who have lost intact auditory nerve function due to the removal of an acoustic neuroma, enabling them to perceive environmental sounds, increase speech recognition, and improve their communication skills. In most patients, their lip-reading ability improves with the use of an ABI device. Some patients are able to converse with others simply by relying on an ABI (without the aid of lip-reading). ABI technology has been used in developed countries for more than 20 years in clinical treatment and has achieved good results . However, it has not yet been carried out in China because of its high price and the difficulty of brainstem surgery and the lack of knowledge of electrophysiology and brainstem tissue reactivity. Now, we, Tiantan Hospital, have developed a domestic ABI electrode. Currently, we are conducting animal experiments, implanting the electrode into the monkey’s brain, and evaluating the safety and effectiveness of the home-made electrode.The localization of the ABI electrode will greatly reduce the cost of electrode implantation, which can improve the hearing condition of more deaf patients, and bring hope to the majority of patients.